QTRX:NASDAQQuanterix Corporation Analysis
Data as of 2026-06-06 - not real-time
$3.30
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Quanterix’s stock is trading at $3.30, which sits just above its 20‑day and 50‑day SMAs but well below the 200‑day SMA, indicating short‑term momentum amid a longer‑term downtrend. The RSI hovers around 53, suggesting neutral buying pressure, while the MACD line is positive and the histogram is expanding, a bullish signal that contrasts with the overall bearish trend flag. Volatility is extreme at over 100% for the past 30 days and beta exceeds 2, pointing to a highly responsive price that can swing sharply on news. Revenue grew 20% YoY to $36.4 M and gross margins are healthy at roughly 45%, yet operating margins are deeply negative (‑59%) and the company posted a loss of $0.39 per share, missing consensus estimates by more than 25%. Cash on hand (~$99 M) comfortably exceeds debt (~$35 M), but free cash flow remains negative and the debt‑to‑equity ratio is elevated, raising concerns about capital sustainability. The CFO’s imminent departure adds a layer of executive uncertainty, and recent earnings calls highlighted both cost‑management improvements and revenue shortfalls versus forecasts. Valuation multiples are low (PB ≈ 0.55, price‑to‑sales ≈ 1.07) and analysts project a median target of $4.00, implying roughly 30% upside if the stock can stabilize. However, the lack of dividend, high drawdown potential (‑68% max drawdown) and a “hold” consensus temper enthusiasm. In summary, the stock shows a blend of growth cues and value appeal but is weighed down by profitability challenges, high volatility, and leadership turnover.
Investors should monitor near‑term earnings guidance, cash‑burn trends, and any replacement for the CFO, while weighing the technical bullish hints against the broader bearish fundamentals before deciding on exposure.
Investors should monitor near‑term earnings guidance, cash‑burn trends, and any replacement for the CFO, while weighing the technical bullish hints against the broader bearish fundamentals before deciding on exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Quarterly loss widened versus consensus
- CFO departure creates executive uncertainty
- Bullish MACD but decreasing volume signals caution
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 20% year‑over‑year revenue growth and solid gross margins
- Low price‑to‑book and price‑to‑sales suggest valuation headroom
- Potential upside to analyst median target around $4.00
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Sustained operating losses and negative free cash flow
- High beta and extreme volatility increase downside risk
- Regulatory and product adoption timelines remain uncertain
Key Metrics & Analysis
Financial Health
Revenue Growth20.10%
Profit Margin-71.86%
P/E Ratio-2.4
ROE-34.81%
ROA-13.39%
Debt/Equity12.52
P/B Ratio0.6
Op. Cash Flow$-81455000
Free Cash Flow$-21983500
Industry P/E27.9
Technical Analysis
TrendBearish
RSI53.5
Support$2.39
Resistance$4.03
MA 20$2.94
MA 50$3.20
MA 200$5.21
MACDBullish
VolumeDecreasing
Fear & Greed Index83.02
Valuation
Target Price$4.33
Upside/Downside31.31%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.04
Volatility106.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.